User made progress with topical Finasteride/Minoxidil and topical Dutasteride for hair loss. Microneedling at 1.5mm daily was also mentioned as part of the treatment.
User shared 126-day progress using Fin/Min/Niz/Microneedling for hair loss. Others discussed microneedling depth, results timeline, frontal coverage, and switching to Dutasteride.
User "hemantch" shares 5 months progress using topical Fin, Min, topical Dut, and a laser cap for hair loss. Significant regrowth was noticed after 1 month, and the treatments worked well despite being bald for 10 years.
User Topher1999 achieved hair regrowth using Dutasteride 3 times a week and microneedling with Dr. Pen Ultima A6 every 2 weeks for 9 months. They believe microneedling is the main reason for hairline gains.
Triple Hair's TH-16, a product claimed to be more effective than Minoxidil 5%, has been released; it contains melatonin and resveratrol. One user reported success with topical melatonin and dermarolling.
User shared their 14-month progress using topical Dutasteride at 0.1% for hair loss, with significant improvement and no side effects. Others discussed concerns about fertility and questioned the authenticity of the results.
The post and conversation are about the long-term side effects of using Dutasteride and Finasteride for hair loss, including issues like raised liver enzymes, high cholesterol, and loss of libido. The user advises regular blood work and careful monitoring for those using these treatments.
The availability of Topical Dutasteride, a potential treatment for hair loss, which can be purchased without prescription from MinoxidilMax. Other treatments discussed include Topical Finasteride and PRP injections, with discussion around dosage, efficacy, side-effects and safety.
The user is considering increasing their dutasteride dose and trying clascoterone or RU58841 for hair loss stabilization. They have used finasteride, minoxidil, and dutasteride, with some success but recent setbacks.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.
Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.
Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.
The user shared their experience with Finasteride and Dutasteride for hair loss. They initially had success with Finasteride but switched to Dutasteride after experiencing shedding, which continued, and are now considering a hair transplant.
The conversation is about the effectiveness of Dutasteride (DUT) for hair loss. Some users have had positive results with DUT, while others have experienced negative effects. Different opinions and experiences are shared, including the mention of Ashton Kutcher using DUT for 20 years without problems.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.
Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.
Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.
The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.
User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.
A user's 8 month progress with treatments including dutasteride, minoxidil, RU58841, derma roller, ketoconazole shampoo and stemoxydine to combat hair loss. Others have shared their own experiences and regrowth results with similar treatments.
The conversation discusses seeking a stronger treatment than Dutasteride (DUT) for hair loss. Suggestions include combining DUT with RU58841, increasing DUT dosage, and using transgender hormone replacement therapy or testosterone blockers, though some options may have feminizing side effects.